Item 1.01. Entry into a Material Definitive Agreement.
On August 18, 2022, HALOZYME THERAPEUTICS, INC. (the "Company") entered into
Amendment No. 1 to the Credit Agreement (the "Amendment") among the Company, the
Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to
time party thereto, BANK OF AMERICA, N.A., as Administrative Agent (in such
capacity, the "Administrative Agent") and swing line lender (in such capacity,
the "Swing Line Lender"), and each lender party thereto, which amends the Credit
Agreement dated as of May 24, 2022 (the "Credit Agreement") among the Company,
the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and
the L/C Issuers. The Amendment, among other things, increases the size of the
revolving credit facility from $350 million to $575 million. The terms of the
revolving credit facility are otherwise unchanged. Concurrently with the entry
into the Amendment, the Company repaid the entire outstanding term loan facility
and repaid all outstanding loans under the revolving credit facility under the
Credit Agreement with a portion of the proceeds of its previously disclosed
issuance of convertible notes.
The foregoing description of the Amendment does not purport to be complete and
is qualified in its entirety by the terms and conditions of the Amendment, which
is included as Exhibit 10.1 and is incorporated herein by reference.
--------------------------------------------------------------------------------
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 is incorporated herein by reference into
this Item 2.03.
Item 9.01.
© Edgar Online, source Glimpses
HALOZYME THERAPEUTICS, INC. 
